EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samplesELLISON, Gillian; GUANSHAN ZHU; MOULIS, Alexandros et al.Journal of clinical pathology. 2013, Vol 66, Num 2, pp 79-89, issn 0021-9746, 11 p.Article

Gefitinib Versus Vinorelbine in Chemotherapy-Naive Elderly Patients With Advanced Non-Small-Cell Lung Cancer (INVITE) : A Randomized, Phase II StudyCRINO, Lucio; CAPPUZZO, Federico; DUFFIELD, Emma L et al.Journal of clinical oncology. 2008, Vol 26, Num 26, pp 4253-4260, issn 0732-183X, 8 p.Article

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancerBRAVE, Sandra R; ODEDRA, Rajesh; WAINWRIGHT, Anna et al.International journal of oncology. 2011, Vol 39, Num 1, pp 271-278, issn 1019-6439, 8 p.Article

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in CancerHICKINSON, D. Mark; KLINOWSKA, Teresa; MILLS, Elizabeth et al.Clinical cancer research (Print). 2010, Vol 16, Num 4, pp 1159-1169, issn 1078-0432, 11 p.Article

Epidermal Growth Factor Receptor Immunohistochemistry : Comparison of Antibodies and Cutoff Points to Predict Benefit From Gefitinib in a Phase 3 Placebo-Controlled Study in Advanced Nonsmall-Cell Lung CancerHIRSCH, Fred R; DZIADZIUSZKO, Rafal; THATCHER, Nick et al.Cancer. 2008, Vol 112, Num 5, pp 1114-1121, issn 0008-543X, 8 p.Article

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non―Small-Cell Lung Cancer in Asia (IPASS)FUKUOKA, Masahiro; WU, Yi-Long; DUFFIELD, Emma L et al.Journal of clinical oncology. 2011, Vol 29, Num 21, pp 2866-2875, issn 0732-183X, 10 p.Article

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non―Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST TrialDOUILLARD, Jean-Yves; SHEPHERD, Frances A; WATKINS, Claire L et al.Journal of clinical oncology. 2010, Vol 28, Num 5, pp 744-752, issn 0732-183X, 9 p.Article

Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and NeckSTEWART, J. Simon W; COHEN, Ezra E. W; VARELLA-GARCIA, Marileila et al.Journal of clinical oncology. 2009, Vol 27, Num 11, pp 1864-1871, issn 0732-183X, 8 p.Article